Quiver Bioscience
Quiver Bioscience develops therapeutics for brain disorders by combining patient-derived human disease models with AI to uncover disease biology and drug targets. The company uses stem-cell–derived neuronal models, high-throughput optogenetic screening, optical electrophysiology, and multi‑omics to generate an information-rich neuronal map and drive target discovery. Quiver integrates proprietary engineering and machine learning to prioritize and optimize candidate molecules, including modalities such as antisense oligonucleotides, and advances programs from target discovery through preclinical development. The company operates as a biotech platform working with pharma and biotech partners to accelerate CNS drug discovery using scalable biology and computational approaches.
Quiver Bioscience
Quiver Bioscience develops therapeutics for brain disorders by combining patient-derived human disease models with AI to uncover disease biology and drug targets. The company uses stem-cell–derived neuronal models, high-throughput optogenetic screening, optical electrophysiology, and multi‑omics to generate an information-rich neuronal map and drive target discovery. Quiver integrates proprietary engineering and machine learning to prioritize and optimize candidate molecules, including modalities such as antisense oligonucleotides, and advances programs from target discovery through preclinical development. The company operates as a biotech platform working with pharma and biotech partners to accelerate CNS drug discovery using scalable biology and computational approaches.
TL;DR
What they do: Develop medicines for brain/CNS disorders using patient-derived neuronal models, high-throughput optogenetic screening, and AI/ML analysis.
Headquarters & founding: Cambridge, Massachusetts — founded 2013 (formerly Q‑State Biosciences).
Platform strengths: Scalable human stem‑cell neuronal models, optical electrophysiology/optogenetic screening, and AI-driven analysis to map neuronal phenotypes and prioritize targets.
Recent funding signal: Grant funding (latest listed round: July 1, 2025) from government research institutes including NINDS; NCI also listed as an investor.
Company Overview
Problem Domain
CNS / brain disorders (examples cited include chronic pain, seizure, and neurodevelopmental disorders).
Founded
2013
Industry
Biotechnology
Tech Stack
Funding Track Record
$2.2M
Crunchbase/Dealroom list this July 2025 grant; Crunchbase reports 4 funding rounds in total and also lists the National Cancer Institute as a recent investor.
Investor Signal
“Government research institutes (listed investors include National Institute of Neurological Disorders and Stroke and National Cancer Institute); funding reported as grant-based.”